Skip to content
Fibrocor Therapeutics
  • Home
  • About Us
    • Leadership
  • Pipeline
    • Discovery
  • Careers
  • Resources
  • News
  • Contact
Search
Fibrocor Therapeutics
Search Toggle menu

Category: News

News

Drug Discovery and the Impact of mAbs
June 19, 2024June 19, 2024News

Drug Discovery and the Impact of mAbs

In another significant mAb collaboration. Fibrocor Therapeutics agreed a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) in March 2024 to advance its Alpon Syndrome programme. Phase I […]

March 5, 2024March 5, 2024News

Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program

Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b Deal is a major step forward for Fibrocor’s plans to […]

January 24, 2024January 24, 2024News

Fibrosis research: Advances and challenges

Fibrocor Therapeutics, a developer of novel therapeutics to treat Fibrosis, recently appointed Piet Wigerinck as Chief Scientific Advisor. Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. DDW’s Megan Thomas caught up […]

January 2, 2024News

Exciting News from Fibrocor Therapeutics!

We are thrilled to announce that an upcoming segment of “Advancements with Ted Danson” will shine a spotlight on advancements in therapeutic treatment and drug discovery capabilities for fibrosis. Join us as we explore the […]

December 19, 2023December 20, 2023News

Meet us in SF @JPM Week 2024!

Meet us in SF @JPM Week 2024! January 8-12, 2024 San Francisco Hilton Financial District Email: [email protected]

Berkshire Innovation Center
November 2, 2023November 2, 2023News, Video

Introduction to Fibrocor filmed at Berkshire Innovation Center

William P. Newsome III, President and CEO, Introduction to Fibrocor filmed at Berkshire Innovation Center’s “Meet the Stage 2 Accelerator” event held at the BIC on September 27, 2023.

October 26, 2023October 26, 2023News

Fibrocor Therapeutics appoints William P. Newsome III as CEO and Piet Wigerinck as Chief Scientific Advisor

Seasoned biopharmaceutical executive to lead Fibrocor as it aims to reshape the future of fibrosis treatment Fibrocor is currently advancing three drug candidates for fibrotic diseases into the clinic Toronto, Canada – 25 October 2023 […]

July 14, 2023August 22, 2023News

FIB992-079 – Clinical Candidate Nomination

It is a small molecule, ATP-competitive kinase inhibitor. The compound is characterized by an exquisite selectivity for its target. This target has been validated with KO-mice in models of lung and kidney fibrosis. FIB992-079 doesn’t […]

June 23, 2023News

Fibrocor Therapeutics Conference Participation 2023

Networking, partnering and debating critical issues: BioEurope: Basel, Switzerland, March 2023 BioEquity Dublin, Ireland May 2023 –Presenter Bio International Convention, Boston, MA, June 202 Jeffries Global Healthcare Conference, New York, NY June  2023

October 1, 2021June 15, 2023News

Piper Sandler Lung Day Conference

Oct 1, 2021 For Immediate Release – Fibrocor Therapeutics Inc, a precision medicine company developing first in class drugs for IPF and other fibrotic diseases, is participating at the upcoming Piper Sandler Lung Day conference […]

Posts pagination

1 2 >

661 University Ave, Suite 1300, Toronto, Ontario, Canada M5G 0B7 || 647.447.2047  || [email protected]

Our Newsletter

Subscribe

* indicates required



Site Navigation

  • Home
  • About Us
    • Leadership
  • Pipeline
    • Discovery
  • Careers
  • Resources
  • News
  • Contact
  • Partners

LinkedIn


YouTube
Copyright © 2024 Fibrocor Therapeutics, Inc
Fibrocor Therapeutics
Close menu
  • Home
  • About Us
    • Leadership
  • Pipeline
    • Discovery
  • Careers
  • Resources
  • News
  • Contact